====== Manish Sadarangani ====== {{ ::manish_sadarangani_mar2019.jpeg?200|}} Dr. **Manish Sadarangani**, MRCPCH, DPHIL, BM.BCh, MA is a Canadian [[infectious diseases]] specialist based in [[canada:british_columbia:Vancouver]], [[canada:British Columbia]]. ===== Affiliations ===== ==== BC Children's Hospital ==== Sadarangani is the Director of the [[Vaccine Evaluation Center]] at the [[BC Children’s Hospital Research Institute]], and the Physician Lead of the Family Immunization Clinic at the [[BC Children's Hospital]].((//Manish Sadarangani.// BC Children’s Hospital Research Institute. Retrieved April 24, 2022, from https://archive.ph/waSOu)) ==== University of British Columbia ==== Sadarangani is an Associate Professor in the Division of Infectious Diseases, Department of Pediatrics ath the [[University of British Columbia]] (UBC). ==== COVID-19 Immunity Task Force ==== Sadarangani is the Principal Investigator of the [[SPRING Study]], funded by the [[COVID-19 Immunity Task Force]].((Wyse, M. //Pediatric Studies.// COVID-19 Immunity Task Force. Retrieved April 24, 2022, from https://archive.ph/G4cQo)) ===== Research ===== ==== Funding ==== Sadarangani has received salary awards from the [[BC Children's Hospital Foundation]], [[Michael Smith Foundation for Health Research]], and the [[Canadian Child Health Clinician Scientist Program]]. He has also received research/project funding (paid to his institution) from [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Moderna]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:Seqirus]], [[pharmaceutical_companies:Symvivo]], and [[pharmaceutical_companies:VBI Vaccines]].((Evans, T., Sadarangani, M., Maguire, J., Zinszer, K., & Kellner, J. (2022). //The importance of pediatric vaccination.// COVID-19 Immunity Task Force. https://web.archive.org/web/20220424080020/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/03/CITF_CanCOVID_6_Pediatric-vaccination_2022_EN_FINAL-2.pdf))